{"parse":{"title":"Pharmaceutical marketing","pageid":956434,"revid":845977771,"text":{"*":"<div class=\"mw-parser-output\"><p>\n<b>Pharmaceutical marketing</b>, sometimes called medico-marketing or pharma marketing in some countries, is the business of advertising or otherwise promoting the sale of <a href=\"/wiki/Pharmaceutical_drug\" class=\"mw-redirect\" title=\"Pharmaceutical drug\">pharmaceutical drugs</a>.<sup id=\"cite_ref-NYT-20151127_1-0\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-NYT-20151219_2-0\" class=\"reference\"><a href=\"#cite_note-NYT-20151219-2\">&#91;2&#93;</a></sup> Many countries have measures in place to limit advertising by <a href=\"/wiki/Pharmaceutical_companies\" class=\"mw-redirect\" title=\"Pharmaceutical companies\">pharmaceutical companies</a>.<sup id=\"cite_ref-NYT-20151127_1-1\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-:0_3-0\" class=\"reference\"><a href=\"#cite_note-:0-3\">&#91;3&#93;</a></sup>\n</p><p>Pharmaceutical company spending on marketing far exceeds that of its research budget.<sup id=\"cite_ref-NYT-20151219_2-1\" class=\"reference\"><a href=\"#cite_note-NYT-20151219-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-Brezis2008_4-0\" class=\"reference\"><a href=\"#cite_note-Brezis2008-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-Women08_5-0\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup> In Canada, $1.7 billion was spent in 2004 to market drugs to physicians; in the  United States, $21 billion was spent in 2002.<sup id=\"cite_ref-McGill04_6-0\" class=\"reference\"><a href=\"#cite_note-McGill04-6\">&#91;6&#93;</a></sup> In 2005, money  spent on pharmaceutical marketing in the United States was estimated at $29.9 billion with one estimate as high as $57 billion.<sup id=\"cite_ref-Women08_5-1\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>  When the U.S. numbers are broken down, 56% was <a href=\"/wiki/Product_sample\" title=\"Product sample\">free samples</a>, 25% was <a href=\"/wiki/Pharmaceutical_sales_representative\" title=\"Pharmaceutical sales representative\">pharmaceutical sales representative</a> \"detailing\" (promoting drugs directly to) physicians, 12.5% was <a href=\"/wiki/Direct_to_user_advertising\" class=\"mw-redirect\" title=\"Direct to user advertising\">direct to user advertising</a>, 4% on detailing to hospitals, and 2% on journal ads.<sup id=\"cite_ref-McGill04_6-1\" class=\"reference\"><a href=\"#cite_note-McGill04-6\">&#91;6&#93;</a></sup> There is some evidence that marketing practices can negatively affect both patients and the health care profession.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#To_health_care_providers[8]\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">To health care providers<sup>&#91;8&#93;</sup></span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#PhRMA_Code\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">PhRMA Code</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Free_samples\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Free samples</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Continuing_medical_education\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Continuing medical education</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Pharmaceutical_representatives\"><span class=\"tocnumber\">1.4</span> <span class=\"toctext\">Pharmaceutical representatives</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Peer_influence\"><span class=\"tocnumber\">1.5</span> <span class=\"toctext\">Peer influence</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Journal_articles_and_technical_documentation\"><span class=\"tocnumber\">1.6</span> <span class=\"toctext\">Journal articles and technical documentation</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Private_and_public_insurers\"><span class=\"tocnumber\">1.7</span> <span class=\"toctext\">Private and public insurers</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-9\"><a href=\"#To_consumers\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">To consumers</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-10\"><a href=\"#Drug_coupons\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Drug coupons</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Economics\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Economics</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#Regulation_and_fraud\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Regulation and fraud</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#European_Union\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">European Union</span></a></li>\n<li class=\"toclevel-2 tocsection-14\"><a href=\"#United_States\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">United States</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-15\"><a href=\"#Evolution_of_marketing\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Evolution of marketing</span></a></li>\n<li class=\"toclevel-1 tocsection-16\"><a href=\"#See_also\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-17\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-18\"><a href=\"#Further_reading\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Further reading</span></a></li>\n</ul>\n</div>\n\n<h2><span id=\"To_health_care_providers.5B8.5D\"></span><span class=\"mw-headline\" id=\"To_health_care_providers[8]\">To health care providers<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup></span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=1\" title=\"Edit section: To health care providers[8]\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Marketing to health-care providers takes three main forms: activity by pharmaceutical sales representatives, provision of drug samples, and sponsoring <a href=\"/wiki/Continuing_medical_education\" title=\"Continuing medical education\">continuing medical education</a> (CME). The use of gifts, including pens and coffee mugs embossed with pharmaceutical product names, has been prohibited by PHRMA ethics guidelines since 2008.<sup id=\"cite_ref-Women08_5-2\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup>\nOf the 237,000 medical sites representing 680,000 physicians surveyed in SK&amp;A's 2010 Physician Access survey, half said they prefer or require an appointment to see a rep (up from 38.5% preferring or requiring an appointment in 2008), while 23% won't see reps at all, according to the survey data.  Practices owned by hospitals or health systems are tougher to get into than private practices, since appointments have to go through headquarters, the survey found.\n13.3% of offices with just one or two doctors won't see representatives, compared with a no-see rate of 42% at offices with 10 or more doctors.\nThe most accessible physicians for promotional purposes are allergists/immunologists \u2013 only 4.2% won't see reps at all \u2013 followed by orthopedic specialists (5.1%) and diabetes specialists (7.6%). Diagnostic radiologists are the most rigid about allowing details \u2013 92.1% won't see reps \u2013 followed by pathologists and neuroradiologists, at 92.1% and 91.8%, respectively.<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup>\n</p><p>E-detailing is widely used to reach \"no see physicians\"; approximately 23% of primary care physicians and 28% of specialists prefer computer-based edetailing, according to survey findings reported in the 25 April 2011, edition of American Medical News (AMNews), published by the American Medical Association (AMA).<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"PhRMA_Code\">PhRMA Code</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=2\" title=\"Edit section: PhRMA Code\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <a href=\"/wiki/Pharmaceutical_Research_and_Manufacturers_of_America\" title=\"Pharmaceutical Research and Manufacturers of America\">Pharmaceutical Research and Manufacturers of America</a> (PhRMA) released updates to its voluntary Code on Interactions with Healthcare Professionals on 10 July 2008. The new guidelines took effect in January 2009.\"<sup id=\"cite_ref-Phrmacode_12-0\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup>\n</p><p>In addition to prohibiting small gifts and reminder items such as pens, notepads, staplers, clipboards, paperweights, pill boxes, etc.,<sup id=\"cite_ref-Phrmacode_12-1\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup> the revised Code:\n</p>\n<ol><li>Prohibits company sales representatives providing restaurant meals to healthcare professionals, but allows them to provide occasional modest meals in healthcare professionals\u2019 offices in conjunction with informational presentations\"<sup id=\"cite_ref-Phrmacode_12-2\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup></li>\n<li>Includes new provisions requiring companies to ensure their representatives are sufficiently trained about applicable laws, regulations, and industry codes of practice and ethics.<sup id=\"cite_ref-Phrmacode_12-3\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup></li>\n<li>Provides that each company will state its intentions to abide by the Code and that company CEOs and compliance officers will certify each year that they have processes in place to comply.<sup id=\"cite_ref-Phrmacode_12-4\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup></li>\n<li>Includes more detailed standards regarding the independence of continuing medical education.<sup id=\"cite_ref-Phrmacode_12-5\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup></li>\n<li>Provides additional guidance and restrictions for speaking and consulting arrangements with healthcare professionals.<sup id=\"cite_ref-Phrmacode_12-6\" class=\"reference\"><a href=\"#cite_note-Phrmacode-12\">&#91;12&#93;</a></sup></li></ol>\n<h3><span class=\"mw-headline\" id=\"Free_samples\">Free samples</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=3\" title=\"Edit section: Free samples\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Free samples have been shown to affect physician prescribing behaviour.  Physicians with access to free samples are more likely to prescribe brand name medication over equivalent generic medications.<sup id=\"cite_ref-Women08_5-3\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>  Other studies found that free samples decreased the likelihood that physicians would follow standard of care practices.<sup id=\"cite_ref-Women08_5-4\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>\n</p><p>Receiving pharmaceutical samples does not reduce prescription costs. Even after receiving samples, sample recipients remain disproportionately burdened by prescription costs.<sup id=\"cite_ref-ncbi.nlm.nih.gov_13-0\" class=\"reference\"><a href=\"#cite_note-ncbi.nlm.nih.gov-13\">&#91;13&#93;</a></sup>\n</p><p>It is argued that a benefit to free samples is the \u201ctry it before you buy it\u201d approach. Free samples give immediate access to the medication and the patient can begin treatment right away.  Also, it saves time from going to a pharmacy to get it filled before treatment begins. Since not all medications work for everyone, and many do not work the same way for each person, free samples allow patients to find which dose and brand of medication works best before having to spend money on a filled prescription at a <a href=\"/wiki/Pharmacy\" title=\"Pharmacy\">pharmacy</a>.<sup id=\"cite_ref-ncbi.nlm.nih.gov_13-1\" class=\"reference\"><a href=\"#cite_note-ncbi.nlm.nih.gov-13\">&#91;13&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Continuing_medical_education\">Continuing medical education</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=4\" title=\"Edit section: Continuing medical education\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Hours spent by physicians in industry-supported <a href=\"/wiki/Continuing_medical_education\" title=\"Continuing medical education\">continuing medical education</a> (CME) is greater than that from either <a href=\"/wiki/Medical_school\" title=\"Medical school\">medical schools</a> or professional societies.<sup id=\"cite_ref-Women08_5-5\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmaceutical_representatives\">Pharmaceutical representatives</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=5\" title=\"Edit section: Pharmaceutical representatives\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Currently, there are approximately 81,000 <a href=\"/wiki/Pharmaceutical_sales_representative\" title=\"Pharmaceutical sales representative\">pharmaceutical sales representatives</a> in the United States<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup> pursuing some 830,000 pharmaceutical prescribers. A pharmaceutical representative will often try to see a given physician every few weeks. Representatives often have a call list of about 200-300 physicians with 120-180 targets that should be visited in 1-2 or 3 week cycle.\n</p><p>Because of the large size of the pharmaceutical sales force, the organization, management, and measurement of effectiveness of the sales force are significant business challenges. Management tasks are usually broken down into the areas of physician targeting, sales force size and structure, sales force optimization, call planning, and sales forces effectiveness. A few pharmaceutical companies have realized that training sales representatives on high science alone is not enough, especially when most products are similar in quality.  Thus, training sales representatives on relationship selling techniques in addition to medical science and product knowledge, can make a difference in sales force effectiveness.  Specialist physicians are relying more and more on specialty sales reps for product information, because they are more knowledgeable than primary care reps.\n</p><p>The United States has 81,000 pharmaceutical representatives or 1 for every 7.9 physicians.<sup id=\"cite_ref-Women08_5-6\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup> The number and persistence of pharmaceutical  representatives has placed a burden on the time of physicians.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup> \"As the  number of reps went up, the amount of time an average rep spent with  doctors went down\u2014so  far down, that tactical scaling has spawned a strategic crisis.  Physicians no longer spend much time with sales reps, nor do they see this as a serious problem.\"\n</p><p>Marketers must  decide on the appropriate size of a sales force needed to sell a  particular portfolio of drugs to the target market. Factors influencing this decision are the optimal reach (how many physicians to see) and frequency (how often to see  them) for each individual physician, how many patients suffer from that disease state, how many sales representatives to devote to office and group practice and how many to devote to hospital accounts if needed. To aid this decision, customers are broken down into different classes according to their prescription behavior, patient population, and of course, their business potential.\n</p><p>Marketers attempt to identify the set of physicians most likely to prescribe a given drug. Historically, this was done by measuring the number of total prescriptions (TRx) and new prescriptions (NRx) per week that each physician writes. This information is collected by commercial vendors. The physicians are then \"deciled\" into ten groups based on their writing patterns. Higher deciles are more aggressively targeted. Some pharmaceutical companies use additional information such as:\n</p>\n<ul><li>Profitability of a prescription (script),</li>\n<li>Accessibility of the physician,</li>\n<li>Tendency of the physician to use the pharmaceutical company's drugs,</li>\n<li>Effect of managed care formularies on the ability of the physician to prescribe a drug,</li>\n<li>The <a href=\"/w/index.php?title=Adoption_sequence&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Adoption sequence (page does not exist)\">adoption sequence</a> of the physician (that is, how readily the physician adopts new drugs in place of older treatments), and</li>\n<li>The tendency of the physician to use a wide palette of drugs</li>\n<li>Influence that physicians have on their colleagues.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup></li></ul>\n<p>Data for drugs prescribed in a hospital are not usually available at the physician level. Advanced analytic techniques are used to value physicians in a hospital setting.<sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup>\n</p><p>Physicians are perhaps the most important component in  sales. They  write the prescriptions that determine which drugs will be used by  people.  Influencing the physician is the key to pharmaceutical sales.  Historically, this was done by a large pharmaceutical sales force. A  medium-sized  pharmaceutical company might have a sales force of 1000  representatives.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (November 2007)\">citation needed</span></a></i>&#93;</sup>  The largest companies have tens of thousands of representatives around  the world. Sales representatives called upon physicians regularly,  providing clinical information, approved journal articles, and free drug samples. This is still the approach  today; however, economic pressures on the industry are causing  pharmaceutical companies to rethink the traditional sales process to  physicians. The industry has seen a large scale adoption of Pharma CRM systems that works on laptops and more recently <a href=\"/wiki/Tablet_computer\" title=\"Tablet computer\">tablets</a>. The new age pharmaceutical representative is armed with key data at his fingertips and tools to maximize the time spent with physicians.\n</p>\n<h3><span class=\"mw-headline\" id=\"Peer_influence\">Peer influence</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=6\" title=\"Edit section: Peer influence\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<dl><dt>Key opinion leaders</dt></dl>\n<p>Key opinion leaders (KOL), or \"thought leaders\", are  respected individuals, such as prominent medical school faculty, who  influence physicians through their professional status. Pharmaceutical  companies generally engage key opinion leaders early in the drug  development process to provide advocacy and key marketing feedback.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup> Some  pharmaceutical companies identify key opinion leaders through direct  inquiry of physicians (primary research).  Recently, pharmaceutical companies have begun to use <a href=\"/wiki/Social_network_analysis\" title=\"Social network analysis\">social network analysis</a> to uncover thought leaders; because it does not introduce respondent bias, which is commonly found in primary research; it can identify and map out the entire scientific community for a disease state; and it has greater compliance with state and federal regulations; because physician prescribing patterns are not used to create the social network.<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup>\n</p><p>Alternatives  to  segmenting physicians purely on the basis of prescribing do exist,  and  marketers can call upon strategic partners who specialize in   delineating which characteristics of true opinion leadership, a   physician does or does not possess.  Such analyses can help guide   marketers in how to optimize KOL engagements as bona fide advisors to a   brand, and can help shape clinical development and clinical data   publication plans for instance, ultimately advancing patient care.\n</p>\n<dl><dt>Colleagues</dt></dl>\n<p>Physicians  acquire information through informal contacts with their colleagues,  including social events, professional affiliations, common hospital  affiliations, and common medical school affiliations. Some  pharmaceutical companies identify influential colleagues through  commercially available prescription writing and patient level data.<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup>\nDoctor  dinner meetings are an effective way for physicians to acquire  educational information from respected peers.  These meetings are  sponsored by some pharmaceutical companies.\n</p>\n<h3><span class=\"mw-headline\" id=\"Journal_articles_and_technical_documentation\">Journal articles and technical documentation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=7\" title=\"Edit section: Journal articles and technical documentation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Recent legal cases and US congressional  hearings have provided access to <a href=\"/wiki/Drug_Industry_Document_Archive\" class=\"mw-redirect\" title=\"Drug Industry Document Archive\">pharmaceutical industry documents</a>  revealing new marketing strategies for drugs.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup>  Activities  once considered independent of promotional intent, including <a href=\"/wiki/Continuing_medical_education\" title=\"Continuing medical education\">continuing medical education</a> and <a href=\"/wiki/Medical_research\" title=\"Medical research\">medical research</a>,  are used, including paying to publish articles about promoted drugs for  the medical literature, and alleged suppression of unfavorable study  results.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Private_and_public_insurers\">Private and public insurers</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=8\" title=\"Edit section: Private and public insurers\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Public and private insurers affect the writing of prescriptions by physicians through <a href=\"/wiki/Formulary_(pharmacy)\" title=\"Formulary (pharmacy)\">formularies</a> that restrict the number and types of drugs that the insurer will cover. Not only can the insurer affect drug sales by including or excluding a particular drug from a formulary, they can affect sales by tiering, or placing bureaucratic hurdles to prescribing certain drugs. In January 2006, the United States instituted a new public prescription drug plan through its <a href=\"/wiki/Medicare_(United_States)\" title=\"Medicare (United States)\">Medicare</a> program. Known as <a href=\"/wiki/Medicare_Part_D\" title=\"Medicare Part D\">Medicare Part&#160;D</a>, this program engages private insurers to negotiate with <a href=\"/wiki/Pharmaceutical_company\" class=\"mw-redirect\" title=\"Pharmaceutical company\">pharmaceutical companies</a> for the placement of drugs on tiered formularies.\n</p>\n<h2><span class=\"mw-headline\" id=\"To_consumers\">To consumers</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=9\" title=\"Edit section: To consumers\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Only two countries as of 2008 allow <a href=\"/wiki/Direct_to_consumer_advertising\" class=\"mw-redirect\" title=\"Direct to consumer advertising\">direct to consumer advertising</a> (DTCA): the United States and New Zealand.<sup id=\"cite_ref-NYT-20151127_1-2\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-:0_3-1\" class=\"reference\"><a href=\"#cite_note-:0-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-Women08_5-7\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup> Since the late 1970s, DTCA of prescription drugs has become important in the United States. It takes two main forms: the promotion or creation of a disease out of a non-pathologic physical condition or the promotion of a medication.<sup id=\"cite_ref-Women08_5-8\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup> The rhetorical objective of direct-to-consumer advertising is to directly influence the patient-physician dialogue.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup> Many patients will inquire about, or even demand a medication they have seen advertised on television.<sup id=\"cite_ref-NYT-20151127_1-3\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup> In the United States, recent years have seen an increase in mass media advertisements for pharmaceuticals.\nExpenditures on direct-to-users advertising have more than quintupled in the seven years between 1997 and 2005 since the FDA changed the guidelines, from $1.1 billion in 1997 to more than $4.2 billion in 2005, a 19.6% annual increase, according to the United States <a href=\"/wiki/Government_Accountability_Office\" title=\"Government Accountability Office\">Government Accountability Office</a>, 2006).<sup id=\"cite_ref-Women08_5-9\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>\n</p><p>The mass marketing to users of  pharmaceuticals is banned in over 30 industrialized nations, but not in  the US and <a href=\"/wiki/New_Zealand\" title=\"New Zealand\">New Zealand</a>,<sup id=\"cite_ref-NYT-20151127_1-4\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup> which is considering a ban.<sup id=\"cite_ref-www.chmeds.ac.nz_24-0\" class=\"reference\"><a href=\"#cite_note-www.chmeds.ac.nz-24\">&#91;24&#93;</a></sup> Some feel it  is better to leave the decision wholly in the hands of medical professionals; others feel that users education and participation in health is useful, but users need independent, comparative information about drugs (not promotional information).<sup id=\"cite_ref-NYT-20151127_1-5\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-www.chmeds.ac.nz_24-1\" class=\"reference\"><a href=\"#cite_note-www.chmeds.ac.nz-24\">&#91;24&#93;</a></sup> For these  reasons, most countries impose limits on pharmaceutical mass marketing that are not placed on the marketing of other products. In some areas it is required that ads for drugs include a list of possible side effects, so that users are informed of both facets of a medicine. <a href=\"/wiki/Canada\" title=\"Canada\">Canada</a>'s limitations on pharmaceutical advertising ensure that commercials that mention the name of a product cannot in any way describe what it does. Commercials that mention a medical problem cannot also mention the name of the product for sale; at most, they can direct the viewer to a website or telephone number operated by the pharmaceutical company.\n</p><p>Reynold Spector has provided examples of how positive and negative hype can affect perceptions of pharmaceuticals using examples of certain cancer drugs, such as <a href=\"/wiki/Avastin\" class=\"mw-redirect\" title=\"Avastin\">Avastin</a> and <a href=\"/wiki/Opdivo\" class=\"mw-redirect\" title=\"Opdivo\">Opdivo</a>, in the former case and <a href=\"/wiki/Statin\" title=\"Statin\">statins</a> in the latter.<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Drug_coupons\">Drug coupons</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=10\" title=\"Edit section: Drug coupons\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In the United States, pharmaceutical companies often provide <a href=\"/wiki/Drug_coupon\" title=\"Drug coupon\">drug coupons</a> to consumers to help offset the <a href=\"/wiki/Copayment\" title=\"Copayment\">copayments</a> charged by health insurers for prescription medication. These coupons are generally used to promote medications that compete with non-preferred products and cheaper, generic alternatives by reducing or eliminating the extra out-of-pocket costs that an insurers typically charge a patient for a non-preferred drug product.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Economics\">Economics</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=11\" title=\"Edit section: Economics\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Pharmaceutical company spending on marketing exceeds that spent on research.<sup id=\"cite_ref-Brezis2008_4-1\" class=\"reference\"><a href=\"#cite_note-Brezis2008-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-Women08_5-10\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>  In 2004 in Canada $1.7 billion a year was spent marketing drugs to physicians and in the United States $21 billion were spent in 2002.<sup id=\"cite_ref-McGill04_6-2\" class=\"reference\"><a href=\"#cite_note-McGill04-6\">&#91;6&#93;</a></sup>  In 2005 money spent on pharmaceutical marketing in the United States was estimated at $29.9 billion with one estimate as high as $57 billion.<sup id=\"cite_ref-Women08_5-11\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>  When the US number are broken down 56% was free samples, 25% was detailing of physicians, 12.5% was direct to users advertising, 4% on hospital detailing, and 2% on journal ads.<sup id=\"cite_ref-McGill04_6-3\" class=\"reference\"><a href=\"#cite_note-McGill04-6\">&#91;6&#93;</a></sup> In the United States approximately $20 billion could be saved if generics were used instead of equivalent brand name products.<sup id=\"cite_ref-Women08_5-12\" class=\"reference\"><a href=\"#cite_note-Women08-5\">&#91;5&#93;</a></sup>\n</p><p>Although pharmaceutical companies have made large investments in marketing their products, overall promotional spending has been decreasing over the last few years, and declined by 10 percent from 2009 to 2010. Pharmaceutical companies are cutting back mostly in detailing and sampling, while spending in mailings and print advertising grew since last year.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Regulation_and_fraud\">Regulation and fraud</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=12\" title=\"Edit section: Regulation and fraud\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"European_Union\">European Union</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=13\" title=\"Edit section: European Union\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<table class=\"plainlinks metadata ambox mbox-small-left ambox-content\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><a href=\"/wiki/File:Wiki_letter_w_cropped.svg\" class=\"image\"><img alt=\"[icon]\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/20px-Wiki_letter_w_cropped.svg.png\" width=\"20\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/30px-Wiki_letter_w_cropped.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1c/Wiki_letter_w_cropped.svg/40px-Wiki_letter_w_cropped.svg.png 2x\" data-file-width=\"44\" data-file-height=\"31\" /></a></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This section <b>needs expansion</b>. <small>You can help by <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=\">adding to it</a>.</small>  <small><i>(February 2016)</i></small></div></td></tr></tbody></table>\n<p>In the European Union, marketing of pharmaceuticals is regulated by EU (formerly EEC) <a href=\"/w/index.php?title=Directive_92/28/EEC&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Directive 92/28/EEC (page does not exist)\">Directive 92/28/EEC</a>.<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> Among other things, it requires member states to prohibit off-label marketing, and direct-to-consumer marketing of prescription-only medications.\n</p>\n<h3><span class=\"mw-headline\" id=\"United_States\">United States</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=14\" title=\"Edit section: United States\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">See also: <a href=\"/wiki/List_of_largest_pharmaceutical_settlements\" title=\"List of largest pharmaceutical settlements\">List of largest pharmaceutical settlements</a> and <a href=\"/wiki/List_of_off-label_promotion_pharmaceutical_settlements\" title=\"List of off-label promotion pharmaceutical settlements\">List of off-label promotion pharmaceutical settlements</a></div>\n<p>In the United States, marketing and distribution of pharmaceuticals is regulated by the <a href=\"/wiki/Federal_Food,_Drug,_and_Cosmetic_Act\" title=\"Federal Food, Drug, and Cosmetic Act\">Federal Food, Drug, and Cosmetic Act</a> and the <a href=\"/wiki/Prescription_Drug_Marketing_Act\" title=\"Prescription Drug Marketing Act\">Prescription Drug Marketing Act</a>, respectively. <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">Food and Drug Administration</a> (FDA) regulations require all prescription drug promotion to be truthful and not misleading, based on \"substantial evidence or substantial clinical experience\", to provide a \"fair balance\" between the risks and benefits of the promoted drug, and to maintain consistency with labeling approved by the FDA. The FDA Office of Prescription Drug Promotion enforces these requirements.\n</p><p>In the 1990s, antipsychotics were \"still seen as treatments for the most serious mental illnesses, like hallucinatory schizophrenia, and recast them for much broader uses\". Drugs such as <a href=\"/wiki/Abilify\" class=\"mw-redirect\" title=\"Abilify\">Abilify</a> and <a href=\"/wiki/Geodon\" class=\"mw-redirect\" title=\"Geodon\">Geodon</a> were given to a broad range of patients, from preschoolers to octogenarians. In 2010, more than a half-million youths took antipsychotic drugs, and one-quarter of nursing-home residents have used them. Yet the government warns that the drugs may be fatal to some older patients and have unknown effects on children.<sup id=\"cite_ref-bied2010_29-0\" class=\"reference\"><a href=\"#cite_note-bied2010-29\">&#91;29&#93;</a></sup>\n</p><p>Every major company selling the drugs\u2014<a href=\"/wiki/Bristol-Myers_Squibb\" title=\"Bristol-Myers Squibb\">Bristol-Myers Squibb</a>, <a href=\"/wiki/Eli_Lilly\" title=\"Eli Lilly\">Eli Lilly</a>, <a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a>, <a href=\"/wiki/AstraZeneca\" title=\"AstraZeneca\">AstraZeneca</a>, and <a href=\"/wiki/Johnson_%26_Johnson\" title=\"Johnson &amp; Johnson\">Johnson &amp; Johnson</a>\u2014has either settled recent government cases, under the False Claims Act, for hundreds of millions of dollars or is currently under investigation for possible health care fraud. Following charges of illegal marketing, two of the settlements in 2009 set records for the largest criminal fines ever imposed on corporations. One involved Eli Lilly\u2019s antipsychotic <a href=\"/wiki/Zyprexa\" class=\"mw-redirect\" title=\"Zyprexa\">Zyprexa</a>, and the other involved  <a href=\"/wiki/Bextra\" class=\"mw-redirect\" title=\"Bextra\">Bextra</a>. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, <a href=\"/wiki/Geodon\" class=\"mw-redirect\" title=\"Geodon\">Geodon</a>; Pfizer settled that part of the claim for $301 million, without admitting any wrongdoing.<sup id=\"cite_ref-bied2010_29-1\" class=\"reference\"><a href=\"#cite_note-bied2010-29\">&#91;29&#93;</a></sup>\n</p><p>The following is a list of the four largest settlements reached with <a href=\"/wiki/Pharmaceutical_industry\" title=\"Pharmaceutical industry\">pharmaceutical companies</a> from 1991 to 2012, rank ordered by the size of the total settlement. Legal claims against the pharmaceutical industry have varied widely over the past two decades, including <a href=\"/wiki/Medicare_fraud\" title=\"Medicare fraud\">Medicare and Medicaid fraud</a>, <a href=\"/wiki/Off-label_use\" title=\"Off-label use\">off-label</a> promotion, and inadequate manufacturing practices.<sup id=\"cite_ref-30\" class=\"reference\"><a href=\"#cite_note-30\">&#91;30&#93;</a></sup><sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<th>Company</th>\n<th>Settlement</th>\n<th>Violation(s)</th>\n<th>Year</th>\n<th>Product(s)</th>\n<th>Laws allegedly violated (if applicable)\n</th></tr>\n<tr>\n<td><a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a><sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup></td>\n<td>$3 billion</td>\n<td>Off-label promotion/failure to disclose safety data</td>\n<td>2012</td>\n<td><a href=\"/wiki/Rosiglitazone\" title=\"Rosiglitazone\">Avandia</a>/<a href=\"/wiki/Bupropion\" title=\"Bupropion\">Wellbutrin</a>/<a href=\"/wiki/Paroxetine\" title=\"Paroxetine\">Paxil</a></td>\n<td><a href=\"/wiki/False_Claims_Act\" title=\"False Claims Act\">False Claims Act</a>/<a href=\"/wiki/Federal_Food,_Drug,_and_Cosmetic_Act\" title=\"Federal Food, Drug, and Cosmetic Act\">FDCA</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a><sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup></td>\n<td>$2.3 billion</td>\n<td>Off-label promotion/<a href=\"/wiki/Political_corruption#Kickbacks\" title=\"Political corruption\">kickbacks</a></td>\n<td>2009</td>\n<td><a href=\"/wiki/Valdecoxib\" title=\"Valdecoxib\">Bextra</a>/<a href=\"/wiki/Ziprasidone\" title=\"Ziprasidone\">Geodon</a>/<a href=\"/wiki/Linezolid\" title=\"Linezolid\">Zyvox</a>/<a href=\"/wiki/Pregabalin\" title=\"Pregabalin\">Lyrica</a></td>\n<td>False Claims Act/FDCA\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Abbott_Laboratories\" title=\"Abbott Laboratories\">Abbott Laboratories</a><sup id=\"cite_ref-34\" class=\"reference\"><a href=\"#cite_note-34\">&#91;34&#93;</a></sup></td>\n<td>$1.5 billion</td>\n<td>Off-label promotion</td>\n<td>2012</td>\n<td><a href=\"/wiki/Valproic_acid\" class=\"mw-redirect\" title=\"Valproic acid\">Depakote</a></td>\n<td>False Claims Act/FDCA\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly</a><sup id=\"cite_ref-35\" class=\"reference\"><a href=\"#cite_note-35\">&#91;35&#93;</a></sup></td>\n<td>$1.4 billion</td>\n<td>Off-label promotion</td>\n<td>2009</td>\n<td><a href=\"/wiki/Olanzapine\" title=\"Olanzapine\">Zyprexa</a></td>\n<td>False Claims Act/FDCA\n</td></tr></tbody></table>\n<h2><span class=\"mw-headline\" id=\"Evolution_of_marketing\">Evolution of marketing</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=15\" title=\"Edit section: Evolution of marketing\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The emergence of  new media and technologies in recent years is quickly changing the  pharmaceutical marketing landscape in the United States. Both physicians  and users are increasing their reliance on the Internet as a source of health and medical information, prompting pharmaceutical marketers to look at digital channels for opportunities to reach their target  audiences.\n</p><p>In 2008, 84% of U.S. physicians used the  Internet and other technologies to access pharmaceutical, biotech or  medical device information\u2014a 20% increase from 2004. At the same time, sales reps are  finding it more difficult to get time with doctors for in-person details.  Pharmaceutical companies are exploring online marketing as an alternative way to reach physicians. Emerging e-promotional activities include live video detailing, online events, electronic sampling, and physician customer service portals such as PV Updates, MDLinx, Aptus Health (former Physicians Interactive), and <a href=\"/wiki/Epocrates\" title=\"Epocrates\">Epocrates</a>.\n</p><p>Direct-to-users  marketers are also recognizing the need to shift to digital channels as audiences become more fragmented and the number of access points for news, entertainment and information multiplies. Standard television,  radio and print direct-to-users (DTC) advertisements are less relevant than in the past, and companies  are beginning to focus more on digital marketing efforts like product websites, <a href=\"/wiki/Display_advertising\" title=\"Display advertising\">online display advertising</a>, <a href=\"/wiki/Search_engine_marketing\" title=\"Search engine marketing\">search engine marketing</a>, <a href=\"/wiki/Social_media\" title=\"Social media\">social media</a> campaigns, place-based media and <a href=\"/wiki/Mobile_advertising\" title=\"Mobile advertising\">mobile advertising</a> to reach the over 145 million U.S. adults online for health information.  \n</p><p>In 2010, the <a href=\"/wiki/Food_and_Drug_Administration\" title=\"Food and Drug Administration\">FDA</a>'s Division of Drug Marketing, Advertising and Communications issued a warning letter concerning two unbranded consumer targeted Web sites sponsored by <a href=\"/wiki/Novartis\" title=\"Novartis\">Novartis</a> Pharmaceuticals Corporation as the websites promoted a drug for an unapproved use, the websites failed to disclose the risks associated with the use of the drug and made unsubstantiated dosing claims.<sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=16\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"div-col columns column-width\" style=\"-moz-column-width: 27em; -webkit-column-width: 27em; column-width: 27em;\">\n<ul><li><i><a href=\"/wiki/Big_Pharma_(book)\" title=\"Big Pharma (book)\">Big Pharma: How the World's Biggest Drug Companies Control Illness</a></i> (2006) by Jacky Law</li>\n<li><i><a href=\"/wiki/Side_Effects_(Bass_book)\" title=\"Side Effects (Bass book)\">Side Effects</a></i> (2008) by <a href=\"/wiki/Alison_Bass\" title=\"Alison Bass\">Alison Bass</a></li>\n<li><i><a href=\"/wiki/Bad_Pharma\" title=\"Bad Pharma\">Bad Pharma</a></i> (2012) by <a href=\"/wiki/Ben_Goldacre\" title=\"Ben Goldacre\">Ben Goldacre</a></li>\n<li><a href=\"/wiki/Disease_mongering\" title=\"Disease mongering\">Disease mongering</a></li>\n<li><a href=\"/wiki/Ethics_in_pharmaceutical_sales\" title=\"Ethics in pharmaceutical sales\">Ethics in pharmaceutical sales</a></li>\n<li><a href=\"/wiki/Inverse_benefit_law\" title=\"Inverse benefit law\">Inverse benefit law</a></li>\n<li><a href=\"/wiki/National_pharmaceuticals_policy\" class=\"mw-redirect\" title=\"National pharmaceuticals policy\">National pharmaceuticals policy</a></li>\n<li><a href=\"/wiki/Prescription_Drug_Marketing_Act_(PDMA)\" class=\"mw-redirect\" title=\"Prescription Drug Marketing Act (PDMA)\">Prescription Drug Marketing Act (PDMA)</a></li>\n<li><a href=\"/wiki/Prescription_drug_prices_in_the_United_States\" title=\"Prescription drug prices in the United States\">Prescription drug prices in the United States</a></li></ul>\n</div>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=17\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-NYT-20151127-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NYT-20151127_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">The Editorial Board (27 November 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2015/11/27/opinion/turn-the-volume-down-on-drug-ads.html\">\"Turn the Volume Down on Drug Ads\"</a>. <i><a href=\"/wiki/New_York_Times\" class=\"mw-redirect\" title=\"New York Times\">New York Times</a></i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 November</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Turn+the+Volume+Down+on+Drug+Ads&amp;rft.date=2015-11-27&amp;rft.au=The+Editorial+Board&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F11%2F27%2Fopinion%2Fturn-the-volume-down-on-drug-ads.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NYT-20151219-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NYT-20151219_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NYT-20151219_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">The Editorial Board (19 December 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2015/12/20/opinion/sunday/no-justification-for-high-drug-prices.html\">\"No Justification for High Drug Prices\"</a>. <i><a href=\"/wiki/New_York_Times\" class=\"mw-redirect\" title=\"New York Times\">New York Times</a></i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">20 December</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=No+Justification+for+High+Drug+Prices&amp;rft.date=2015-12-19&amp;rft.au=The+Editorial+Board&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F12%2F20%2Fopinion%2Fsunday%2Fno-justification-for-high-drug-prices.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:0-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_3-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mogull, Scott A. (2008). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.academia.edu/278465/Chronology_of_Direct-to-Consumer_Advertising_Regulation_in_the_United_States\">\"Chronology of Direct-to-Consumer Advertising Regulation in the United States\"</a>. <i>AMWA Journal</i>. <b>23</b>: 3.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AMWA+Journal&amp;rft.atitle=Chronology+of+Direct-to-Consumer+Advertising+Regulation+in+the+United+States&amp;rft.volume=23&amp;rft.pages=3&amp;rft.date=2008&amp;rft.aulast=Mogull&amp;rft.aufirst=Scott+A.&amp;rft_id=https%3A%2F%2Fwww.academia.edu%2F278465%2FChronology_of_Direct-to-Consumer_Advertising_Regulation_in_the_United_States&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Brezis2008-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Brezis2008_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Brezis2008_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Brezis M (2008). \"Big  pharma and health care: unsolvable conflict of interests between private  enterprise and public health\". <i>Isr J Psychiatry Relat Sci</i>. <b>45</b> (2): 83\u20139; discussion 90\u20134. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18982834\">18982834</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Isr+J+Psychiatry+Relat+Sci&amp;rft.atitle=Big++pharma+and+health+care%3A+unsolvable+conflict+of+interests+between+private++enterprise+and+public+health&amp;rft.volume=45&amp;rft.issue=2&amp;rft.pages=83-9%3B+discussion+90-4&amp;rft.date=2008&amp;rft_id=info%3Apmid%2F18982834&amp;rft.au=Brezis+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Women08-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Women08_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Women08_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Women08_5-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Women08_5-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Women08_5-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Women08_5-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Women08_5-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-Women08_5-7\"><sup><i><b>h</b></i></sup></a> <a href=\"#cite_ref-Women08_5-8\"><sup><i><b>i</b></i></sup></a> <a href=\"#cite_ref-Women08_5-9\"><sup><i><b>j</b></i></sup></a> <a href=\"#cite_ref-Women08_5-10\"><sup><i><b>k</b></i></sup></a> <a href=\"#cite_ref-Women08_5-11\"><sup><i><b>l</b></i></sup></a> <a href=\"#cite_ref-Women08_5-12\"><sup><i><b>m</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Sufrin CB, Ross JS (September 2008). \"Pharmaceutical industry marketing: understanding its impact on women's health\". <i>Obstet Gynecol Surv</i>. <b>63</b> (9): 585\u201396. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/OGX.0b013e31817f1585\">10.1097/OGX.0b013e31817f1585</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18713478\">18713478</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Obstet+Gynecol+Surv&amp;rft.atitle=Pharmaceutical+industry+marketing%3A+understanding+its+impact+on+women%27s+health&amp;rft.volume=63&amp;rft.issue=9&amp;rft.pages=585-96&amp;rft.date=2008-09&amp;rft_id=info%3Adoi%2F10.1097%2FOGX.0b013e31817f1585&amp;rft_id=info%3Apmid%2F18713478&amp;rft.aulast=Sufrin&amp;rft.aufirst=CB&amp;rft.au=Ross%2C+JS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-McGill04-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-McGill04_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-McGill04_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-McGill04_6-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-McGill04_6-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.medicine.mcgill.ca/MJM/issues/v08n01/orig_articles/barfett.pdf\">\"www.medicine.mcgill.ca\"</a> <span style=\"font-size:85%;\">(PDF)</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=www.medicine.mcgill.ca&amp;rft_id=http%3A%2F%2Fwww.medicine.mcgill.ca%2FMJM%2Fissues%2Fv08n01%2Forig_articles%2Fbarfett.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Landefeld C. S.; Steinman MA (January 2009). \"The Neurontin legacy: marketing through misinformation and manipulation\". <i>N. Engl. J. Med</i>. <b>360</b> (2): 103\u20136. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMp0808659\">10.1056/NEJMp0808659</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19129523\">19129523</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.atitle=The+Neurontin+legacy%3A+marketing+through+misinformation+and+manipulation&amp;rft.volume=360&amp;rft.issue=2&amp;rft.pages=103-6&amp;rft.date=2009-01&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMp0808659&amp;rft_id=info%3Apmid%2F19129523&amp;rft.au=Landefeld+C.+S.&amp;rft.au=Steinman+MA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Fugh-Berman, Adriane (April 2007). <a rel=\"nofollow\" class=\"external text\" href=\"http://web.law.columbia.edu/sites/default/files/microsites/attorneys-general/files/Following_the_Script.pdf\">\"Following the Script: How Drug Reps Make Friends and Infl uence Doctors\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>PLoS Medicine</i>. <b>4</b>: e150. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1371/journal.pmed.0040150\">10.1371/journal.pmed.0040150</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC1876413\">1876413</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/17455991\">17455991</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PLoS+Medicine&amp;rft.atitle=Following+the+Script%3A+How+Drug+Reps+Make+Friends+and+Infl+uence+Doctors&amp;rft.volume=4&amp;rft.pages=e150&amp;rft.date=2007-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1876413&amp;rft_id=info%3Apmid%2F17455991&amp;rft_id=info%3Adoi%2F10.1371%2Fjournal.pmed.0040150&amp;rft.aulast=Fugh-Berman&amp;rft.aufirst=Adriane&amp;rft_id=http%3A%2F%2Fweb.law.columbia.edu%2Fsites%2Fdefault%2Ffiles%2Fmicrosites%2Fattorneys-general%2Ffiles%2FFollowing_the_Script.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://usatoday30.usatoday.com/money/economy/2008-07-10-3919705145_x.htm\">\"New pharma ethics rules eliminate gifts and meals - USATODAY.com\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=New+pharma+ethics+rules+eliminate+gifts+and+meals+-+USATODAY.com&amp;rft_id=http%3A%2F%2Fusatoday30.usatoday.com%2Fmoney%2Feconomy%2F2008-07-10-3919705145_x.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.mmm-online.com/docs-are-visited-by-20-reps-a-week-survey-says/article/180995/\">\"SK&amp;A's 2010 Physician Access Survey\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=SK%26A%27s+2010+Physician+Access+Survey&amp;rft_id=http%3A%2F%2Fwww.mmm-online.com%2Fdocs-are-visited-by-20-reps-a-week-survey-says%2Farticle%2F180995%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.mmslists.com/news-articles/article.asp?ID=9\">\"Less than 30% of doctors prefer detailing, according to surveys: Doctor emails are primary promotional method\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Less+than+30%25+of+doctors+prefer+detailing%2C+according+to+surveys%3A+Doctor+emails+are+primary+promotional+method&amp;rft_id=http%3A%2F%2Fwww.mmslists.com%2Fnews-articles%2Farticle.asp%3FID%3D9&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Phrmacode-12\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Phrmacode_12-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Phrmacode_12-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Phrmacode_12-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Phrmacode_12-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Phrmacode_12-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-Phrmacode_12-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-Phrmacode_12-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.phrma.org/sites/default/files/pdf/phrma_marketing_code_2008.pdf\">\"Code on Interactions with Healthcare Professionals\"</a> <span style=\"font-size:85%;\">(PDF)</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Code+on+Interactions+with+Healthcare+Professionals&amp;rft_id=http%3A%2F%2Fwww.phrma.org%2Fsites%2Fdefault%2Ffiles%2Fpdf%2Fphrma_marketing_code_2008.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ncbi.nlm.nih.gov-13\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-ncbi.nlm.nih.gov_13-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-ncbi.nlm.nih.gov_13-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Alexander GC, Zhang J, Basu A (2008). \"Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs\". <i>Medical Care</i>. <b>46</b>: 394\u2013402. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/MLR.0b013e3181618ee0\">10.1097/MLR.0b013e3181618ee0</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18362819\">18362819</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Care&amp;rft.atitle=Characteristics+of+patients+receiving+pharmaceutical+samples+and+association+between+sample+receipt+and+out-of-pocket+prescription+costs&amp;rft.volume=46&amp;rft.pages=394-402&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1097%2FMLR.0b013e3181618ee0&amp;rft_id=info%3Apmid%2F18362819&amp;rft.au=Alexander+GC%2C+Zhang+J%2C+Basu+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Multiple names: authors list (<a href=\"/wiki/Category:CS1_maint:_Multiple_names:_authors_list\" title=\"Category:CS1 maint: Multiple names: authors list\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.zsassociates.com/news_events/news_media/the_doctor_wont_see_you_mr_pharma_rep_now/\">\"ZS Associates; Pharmaceutical\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=ZS+Associates%3B+Pharmaceutical&amp;rft_id=http%3A%2F%2Fwww.zsassociates.com%2Fnews_events%2Fnews_media%2Fthe_doctor_wont_see_you_mr_pharma_rep_now%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=177968\">\"www.pharmexec.com\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=www.pharmexec.com&amp;rft_id=http%3A%2F%2Fwww.pharmexec.com%2Fpharmexec%2Farticle%2FarticleDetail.jsp%3Fid%3D177968&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\"><a href=\"/w/index.php?title=Kiefer_Lee&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Kiefer Lee (page does not exist)\">Lee, Kiefer</a>; Carter, Steve (2012). <i>Global Marketing Management</i> (3rd ed.). Oxford University Press. p.&#160;524. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/978-0-19-960970-3\" title=\"Special:BookSources/978-0-19-960970-3\">978-0-19-960970-3</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Global+Marketing+Management&amp;rft.pages=524&amp;rft.edition=3rd&amp;rft.pub=Oxford+University+Press&amp;rft.date=2012&amp;rft.isbn=978-0-19-960970-3&amp;rft.aulast=Lee&amp;rft.aufirst=Kiefer&amp;rft.au=Carter%2C+Steve&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation book\"><a href=\"/w/index.php?title=Nicolae_Sfetcu&amp;action=edit&amp;redlink=1\" class=\"new\" title=\"Nicolae Sfetcu (page does not exist)\">Sfetcu, Nicolae</a>. <i>Health &amp; Drugs: Disease, Prescription &amp; Medication</i>. MultiMedia.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Health+%26+Drugs%3A+Disease%2C+Prescription+%26+Medication&amp;rft.pub=MultiMedia&amp;rft.aulast=Sfetcu&amp;rft.aufirst=Nicolae&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.pharma-mkting.com/glossary/keyopinionleader.htm\">\"Glossary Term: Key Opinion Leader\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Glossary+Term%3A+Key+Opinion+Leader&amp;rft_id=http%3A%2F%2Fwww.pharma-mkting.com%2Fglossary%2Fkeyopinionleader.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.lnxpharma.com/images/pages/Lnx_Whitepaper_1.pdf\">http://www.lnxpharma.com/images/pages/Lnx_Whitepaper_1.pdf</a></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=395598\">\"www.pharmexec.com\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=www.pharmexec.com&amp;rft_id=http%3A%2F%2Fwww.pharmexec.com%2Fpharmexec%2Farticle%2FarticleDetail.jsp%3Fid%3D395598&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.annals.org/cgi/content/abstract/145/4/284\">\"Narrative Review: The Promotion of Gabapentin: An Analysis of  Internal Industry Documents -- Steinman et al. 145 (4): 284 -- Annals of  Internal Medicine\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Narrative+Review%3A+The+Promotion+of+Gabapentin%3A+An+Analysis+of++Internal+Industry+Documents+--+Steinman+et+al.+145+%284%29%3A+284+--+Annals+of++Internal+Medicine&amp;rft_id=http%3A%2F%2Fwww.annals.org%2Fcgi%2Fcontent%2Fabstract%2F145%2F4%2F284&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.annals.org/cgi/content/full/145/4/305?etoc\">\"Safeguarding Patient Welfare: Who's In Charge? -- Henney 145 (4):  305 -- Annals of  Internal Medicine\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Safeguarding+Patient+Welfare%3A+Who%27s+In+Charge%3F+--+Henney+145+%284%29%3A++305+--+Annals+of++Internal+Medicine&amp;rft_id=http%3A%2F%2Fwww.annals.org%2Fcgi%2Fcontent%2Ffull%2F145%2F4%2F305%3Fetoc&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mogull, Scott A.; Balzhiser, Deborah (September 2015). <a rel=\"nofollow\" class=\"external text\" href=\"http://doi.acm.org/10.1145/2826972.2826976\">\"Pharmaceutical Companies Are Writing the Script for Health Consumerism\"</a>. <i>Commun. Des. Q. Rev</i>. <b>3</b> (4): 35\u201349. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1145/2826972.2826976\">10.1145/2826972.2826976</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/2166-1200\">2166-1200</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Commun.+Des.+Q.+Rev&amp;rft.atitle=Pharmaceutical+Companies+Are+Writing+the+Script+for+Health+Consumerism&amp;rft.volume=3&amp;rft.issue=4&amp;rft.pages=35-49&amp;rft.date=2015-09&amp;rft_id=info%3Adoi%2F10.1145%2F2826972.2826976&amp;rft.issn=2166-1200&amp;rft.aulast=Mogull&amp;rft.aufirst=Scott+A.&amp;rft.au=Balzhiser%2C+Deborah&amp;rft_id=http%3A%2F%2Fdoi.acm.org%2F10.1145%2F2826972.2826976&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-www.chmeds.ac.nz-24\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-www.chmeds.ac.nz_24-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-www.chmeds.ac.nz_24-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.chmeds.ac.nz/report.pdf\">\"www.chmeds.ac.nz\"</a> <span style=\"font-size:85%;\">(PDF)</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=www.chmeds.ac.nz&amp;rft_id=http%3A%2F%2Fwww.chmeds.ac.nz%2Freport.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Spector, Reynold (2018). \"Drug Therapy Hype: The Misuse of Data\". <i><a href=\"/wiki/Skeptical_Inquirer\" title=\"Skeptical Inquirer\">Skeptical Inquirer</a></i>. <b>42</b> (2): 44\u201349.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Skeptical+Inquirer&amp;rft.atitle=Drug+Therapy+Hype%3A+The+Misuse+of+Data&amp;rft.volume=42&amp;rft.issue=2&amp;rft.pages=44-49&amp;rft.date=2018&amp;rft.aulast=Spector&amp;rft.aufirst=Reynold&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Lunzer Kritz, Francesca (3 December 2007). <a rel=\"nofollow\" class=\"external text\" href=\"http://articles.latimes.com/2007/dec/03/health/he-coupons3\">\"Check out drug coupons, then check bottom line\"</a>. <i>Los Angeles Times</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">20 November</span> 2011</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Los+Angeles+Times&amp;rft.atitle=Check+out+drug+coupons%2C+then+check+bottom+line&amp;rft.date=2007-12-03&amp;rft.aulast=Lunzer+Kritz&amp;rft.aufirst=Francesca&amp;rft_id=http%3A%2F%2Farticles.latimes.com%2F2007%2Fdec%2F03%2Fhealth%2Fhe-coupons3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://worldofdtcmarketing.com/the-ax-comes-out-for-pharma-promotional-spending/business-of-the-drug-industry/\">\"The ax comes out for pharma promotional spending\"</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+ax+comes+out+for+pharma+promotional+spending&amp;rft_id=http%3A%2F%2Fworldofdtcmarketing.com%2Fthe-ax-comes-out-for-pharma-promotional-spending%2Fbusiness-of-the-drug-industry%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=URISERV:l21143&amp;from=EN\">http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=URISERV:l21143&amp;from=EN</a></span>\n</li>\n<li id=\"cite_note-bied2010-29\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-bied2010_29-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-bied2010_29-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Duff Wilson (2 October 2010). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2010/10/03/business/03psych.html?_r=3&amp;hp=&amp;pagewanted=all\">\"Side Effects May Include Lawsuits\"</a>. <i><a href=\"/wiki/New_York_Times\" class=\"mw-redirect\" title=\"New York Times\">New York Times</a></i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Side+Effects+May+Include+Lawsuits&amp;rft.date=2010-10-02&amp;rft.au=Duff+Wilson&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2010%2F10%2F03%2Fbusiness%2F03psych.html%3F_r%3D3%26hp%3D%26pagewanted%3Dall&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-30\">^</a></b></span> <span class=\"reference-text\">Sammy Almashat, M.D., M.P.H.,  Charles Preston, M.D., M.P.H., Timothy Waterman, B.S., Sidney Wolfe, M.D., \"Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991\u20132010\", Public Citizen\u2019s Health Research Group, December 16, 2010</span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Thomas, Katie; Schmidt, Michael S. (2 July 2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?pagewanted=all\">\"GlaxoSmithKline Agrees to Pay $3 Billion in Fraud Settlement\"</a>. <i>The New York Times</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=GlaxoSmithKline+Agrees+to+Pay+%243+Billion+in+Fraud+Settlement&amp;rft.date=2012-07-02&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft.au=Schmidt%2C+Michael+S.&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2012%2F07%2F03%2Fbusiness%2Fglaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html%3Fpagewanted%3Dall&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.justice.gov/opa/pr/2012/July/12-civ-842.html\">http://www.justice.gov/opa/pr/2012/July/12-civ-842.html</a></span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20-%20PR%20(Final).pdf\">http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20-%20PR%20(Final).pdf</a></span>\n</li>\n<li id=\"cite_note-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-34\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.justice.gov/opa/pr/2012/May/12-civ-585.html\">http://www.justice.gov/opa/pr/2012/May/12-civ-585.html</a></span>\n</li>\n<li id=\"cite_note-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-35\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.justice.gov/opa/pr/2009/January/09-civ-038.html\">http://www.justice.gov/opa/pr/2009/January/09-civ-038.html</a></span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\"><cite id=\"CITEREFDebra_Dunne2010\" class=\"citation\">Debra Dunne (October 4, 2010), <a rel=\"nofollow\" class=\"external text\" href=\"https://www.natlawreview.com/article/unbranded-web-sites-fda-finds-violative-promotional-practices\"><i>Unbranded Web Sites: FDA Finds Violative Promotional Practices</i></a>, Stradley Ronon<span class=\"reference-accessdate\">, retrieved <span class=\"nowrap\">May 22,</span> 2017</span></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Unbranded+Web+Sites%3A+FDA+Finds+Violative+Promotional+Practices&amp;rft.pub=Stradley+Ronon&amp;rft.date=2010-10-04&amp;rft.au=Debra+Dunne&amp;rft_id=https%3A%2F%2Fwww.natlawreview.com%2Farticle%2Funbranded-web-sites-fda-finds-violative-promotional-practices&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div><style data-mw-deduplicate=\"TemplateStyles:r853264625\">.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{list-style-type:none;margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li,.mw-parser-output .refbegin-hanging-indents>dl>dd{margin-left:0;padding-left:3.2em;text-indent:-3.2em;list-style:none}.mw-parser-output .refbegin-100{font-size:100%}</style><div class=\"refbegin\" style=\"\">\n<h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Pharmaceutical_marketing&amp;action=edit&amp;section=18\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><i>Insider's Guide to the World of Pharmaceutical Sales</i>, Seventh Edition (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-9704153-6-2\" title=\"Special:BookSources/0-9704153-6-2\">0-9704153-6-2</a>)</li>\n<li>Merrill Goozner, <i>The $800 million pill</i>. University of California Press, Berkeley 2004, 297 S., <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-520-23945-8\" title=\"Special:BookSources/0-520-23945-8\">0-520-23945-8</a></li>\n<li>Ray Moynihan, Alan Cassels, <i>Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients</i>. Nation Books, New York 2005</li>\n<li><i>Be Brief, Be Bright, Be Gone: Career Essentials for Pharmaceutical Representatives</i> (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-595-17418-3\" title=\"Special:BookSources/0-595-17418-3\">0-595-17418-3</a>)</li>\n<li><i>PharmRepSelect: Your Complete Guide to Getting a Pharmaceutical Sales Job</i> (Pharmrepselect, 1) (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-9724675-1-3\" title=\"Special:BookSources/0-9724675-1-3\">0-9724675-1-3</a>)</li>\n<li><i>The Rx Factor&#160;: Strategic Creativity in Pharmaceutical Marketing</i> (Response Book) (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-8039-9378-1\" title=\"Special:BookSources/0-8039-9378-1\">0-8039-9378-1</a>)</li>\n<li><i>Pharmaceutical Marketing: Principles, Environment, and Practice</i> (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-7890-1582-X\" title=\"Special:BookSources/0-7890-1582-X\">0-7890-1582-X</a>)</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.urchpublishing.com/publications/sales/presentation_plan_00.html\">\"Presentation Planning and Media Relations for the Pharmaceutical Industry\"</a></li>\n<li>Lynn Payer, <i>Disease-Mongers</i>. John Wiley, 1992</li>\n<li><i><a rel=\"nofollow\" class=\"external text\" href=\"http://www.piribo.com/publications/sales_marketing/little_black_book_of_pharma_marketing.html\">Little Black Book of Pharmaceutical Marketing</a></i></li>\n<li><i>How To Conduct Doctor Dinner Meetings</i> (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-9656231-1-4\" title=\"Special:BookSources/0-9656231-1-4\">0-9656231-1-4</a>)</li>\n<li><i><a rel=\"nofollow\" class=\"external text\" href=\"http://www.marketingoverdose.org/documents/ci_pharma_2007.pdf\">Drugs, Doctors and Dinners: How drug companies influence health in the developing world</a></i>. users International, London 2007 (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/1-902391-59-4\" title=\"Special:BookSources/1-902391-59-4\">1-902391-59-4</a>)</li>\n<li><i>360 Degree Selling: How To Sell Biotechnology Products</i> (Paperback) (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-9656231-3-0\" title=\"Special:BookSources/0-9656231-3-0\">0-9656231-3-0</a>)</li>\n<li><i>Selling To Specialist Physicians</i> (Paperback) (<a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-9656231-5-7\" title=\"Special:BookSources/0-9656231-5-7\">0-9656231-5-7</a>)</li>\n<li>Conroy, M. S., <i>The Cosmetics Baron You've Never Heard Of: E.&#160;Virgil Neal and Tokalon</i>, Altus History LLC, (Englewood), 2009. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-615-27278-9\" title=\"Special:BookSources/0-615-27278-9\">0-615-27278-9</a></li>\n<li>Conroy, M. S., <i>The Soviet Pharmaceutical Business During the First Two Decades (1917-1937)</i>, Peter Lang, (New York), 2006. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0-8204-7899-7\" title=\"Special:BookSources/0-8204-7899-7\">0-8204-7899-7</a></li>\n<li><cite class=\"citation journal\">Alexander, G. C.; Zhang, J; Basu, A (2008). \"Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs\". <i>Medical Care</i>. <b>46</b> (4): 394\u2013402. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/MLR.0b013e3181618ee0\">10.1097/MLR.0b013e3181618ee0</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/18362819\">18362819</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Care&amp;rft.atitle=Characteristics+of+patients+receiving+pharmaceutical+samples+and+association+between+sample+receipt+and+out-of-pocket+prescription+costs&amp;rft.volume=46&amp;rft.issue=4&amp;rft.pages=394-402&amp;rft.date=2008&amp;rft_id=info%3Adoi%2F10.1097%2FMLR.0b013e3181618ee0&amp;rft_id=info%3Apmid%2F18362819&amp;rft.aulast=Alexander&amp;rft.aufirst=G.+C.&amp;rft.au=Zhang%2C+J&amp;rft.au=Basu%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APharmaceutical+marketing\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></li></ul>\n</div>\n\n<!-- \nNewPP limit report\nParsed by mw1275\nCached time: 20180909163447\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.440 seconds\nReal time usage: 0.521 seconds\nPreprocessor visited node count: 4525/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 63967/2097152 bytes\nTemplate argument size: 5678/2097152 bytes\nHighest expansion depth: 15/40\nExpensive parser function count: 3/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 39841/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.173/10.000 seconds\nLua memory usage: 4.83 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  449.246      1 -total\n 42.17%  189.466      1 Template:Reflist\n 15.06%   67.644     12 Template:ISBN\n 11.87%   53.337      1 Template:Citation_needed\n 11.20%   50.318      1 Template:Fix\n 11.02%   49.527      5 Template:Cite_news\n  9.69%   43.520      9 Template:Cite_journal\n  8.97%   40.290     13 Template:Cite_web\n  7.87%   35.362      1 Template:Use_dmy_dates\n  7.41%   33.278      2 Template:Category_handler\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:956434-0!canonical and timestamp 20180909163446 and revision id 845977771\n -->\n</div>"},"langlinks":[{"lang":"ar","url":"https://ar.wikipedia.org/wiki/%D8%AA%D8%B3%D9%88%D9%8A%D9%82_%D8%A7%D9%84%D8%A7%D8%AF%D9%88%D9%8A%D8%A9","langname":"Arabic","autonym":"\u0627\u0644\u0639\u0631\u0628\u064a\u0629","*":"\u062a\u0633\u0648\u064a\u0642 \u0627\u0644\u0627\u062f\u0648\u064a\u0629"},{"lang":"fa","url":"https://fa.wikipedia.org/wiki/%D8%A8%D8%A7%D8%B2%D8%A7%D8%B1%DB%8C%D8%A7%D8%A8%DB%8C_%D8%AF%D8%A7%D8%B1%D9%88%DB%8C%DB%8C","langname":"Persian","autonym":"\u0641\u0627\u0631\u0633\u06cc","*":"\u0628\u0627\u0632\u0627\u0631\u06cc\u0627\u0628\u06cc \u062f\u0627\u0631\u0648\u06cc\u06cc"},{"lang":"uk","url":"https://uk.wikipedia.org/wiki/%D0%A4%D0%B0%D1%80%D0%BC%D0%B0%D1%86%D0%B5%D0%B2%D1%82%D0%B8%D1%87%D0%BD%D0%B8%D0%B9_%D1%80%D0%B8%D0%BD%D0%BE%D0%BA","langname":"Ukrainian","autonym":"\u0443\u043a\u0440\u0430\u0457\u043d\u0441\u044c\u043a\u0430","*":"\u0424\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043d\u0438\u0439 \u0440\u0438\u043d\u043e\u043a"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_maint:_Multiple_names:_authors_list"},{"sortkey":"Pharmaceutical Marketing","hidden":"","*":"Use_dmy_dates_from_December_2015"},{"sortkey":"Pharmaceutical Marketing","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"Pharmaceutical Marketing","hidden":"","*":"Articles_with_unsourced_statements_from_November_2007"},{"sortkey":"Pharmaceutical Marketing","hidden":"","*":"Articles_to_be_expanded_from_February_2016"},{"sortkey":"Pharmaceutical Marketing","hidden":"","*":"All_articles_to_be_expanded"},{"sortkey":"Pharmaceutical Marketing","hidden":"","*":"Articles_using_small_message_boxes"},{"sortkey":"Marketing","*":"Pharmaceutical_industry"},{"sortkey":"Marketing","*":"Pharmaceuticals_policy"},{"sortkey":"Marketing","*":"Pharmacy"},{"sortkey":"Pharmaceutical Marketing","*":"Drug_advertising"}],"links":[{"ns":14,"exists":"","*":"Category:Use dmy dates from December 2015"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from November 2007"},{"ns":14,"exists":"","*":"Category:Articles to be expanded from February 2016"},{"ns":14,"exists":"","*":"Category:CS1 maint: Multiple names: authors list"},{"ns":0,"exists":"","*":"Abbott Laboratories"},{"ns":0,"exists":"","*":"Abilify"},{"ns":0,"exists":"","*":"Alison Bass"},{"ns":0,"exists":"","*":"AstraZeneca"},{"ns":0,"exists":"","*":"Avastin"},{"ns":0,"exists":"","*":"Bad Pharma"},{"ns":0,"exists":"","*":"Ben Goldacre"},{"ns":0,"exists":"","*":"Bextra"},{"ns":0,"exists":"","*":"Big Pharma (book)"},{"ns":0,"exists":"","*":"Bristol-Myers Squibb"},{"ns":0,"exists":"","*":"Bupropion"},{"ns":0,"exists":"","*":"Canada"},{"ns":0,"exists":"","*":"Continuing medical education"},{"ns":0,"exists":"","*":"Copayment"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Direct to consumer advertising"},{"ns":0,"exists":"","*":"Direct to user advertising"},{"ns":0,"exists":"","*":"Disease mongering"},{"ns":0,"exists":"","*":"Display advertising"},{"ns":0,"exists":"","*":"Drug Industry Document Archive"},{"ns":0,"exists":"","*":"Drug coupon"},{"ns":0,"exists":"","*":"Eli Lilly"},{"ns":0,"exists":"","*":"Eli Lilly and Company"},{"ns":0,"exists":"","*":"Epocrates"},{"ns":0,"exists":"","*":"Ethics in pharmaceutical sales"},{"ns":0,"exists":"","*":"False Claims Act"},{"ns":0,"exists":"","*":"Federal Food, Drug, and Cosmetic Act"},{"ns":0,"exists":"","*":"Food and Drug Administration"},{"ns":0,"exists":"","*":"Formulary (pharmacy)"},{"ns":0,"exists":"","*":"Geodon"},{"ns":0,"exists":"","*":"GlaxoSmithKline"},{"ns":0,"exists":"","*":"Government Accountability Office"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"Inverse benefit law"},{"ns":0,"exists":"","*":"Johnson & Johnson"},{"ns":0,"exists":"","*":"Linezolid"},{"ns":0,"exists":"","*":"List of largest pharmaceutical settlements"},{"ns":0,"exists":"","*":"List of off-label promotion pharmaceutical settlements"},{"ns":0,"exists":"","*":"Medical research"},{"ns":0,"exists":"","*":"Medical school"},{"ns":0,"exists":"","*":"Medicare (United States)"},{"ns":0,"exists":"","*":"Medicare Part D"},{"ns":0,"exists":"","*":"Medicare fraud"},{"ns":0,"exists":"","*":"Mobile advertising"},{"ns":0,"exists":"","*":"National pharmaceuticals policy"},{"ns":0,"exists":"","*":"New York Times"},{"ns":0,"exists":"","*":"New Zealand"},{"ns":0,"exists":"","*":"Novartis"},{"ns":0,"exists":"","*":"Off-label use"},{"ns":0,"exists":"","*":"Olanzapine"},{"ns":0,"exists":"","*":"Opdivo"},{"ns":0,"exists":"","*":"Paroxetine"},{"ns":0,"exists":"","*":"Pfizer"},{"ns":0,"exists":"","*":"Pharmaceutical Research and Manufacturers of America"},{"ns":0,"exists":"","*":"Pharmaceutical companies"},{"ns":0,"exists":"","*":"Pharmaceutical company"},{"ns":0,"exists":"","*":"Pharmaceutical drug"},{"ns":0,"exists":"","*":"Pharmaceutical industry"},{"ns":0,"exists":"","*":"Pharmaceutical sales representative"},{"ns":0,"exists":"","*":"Pharmacy"},{"ns":0,"exists":"","*":"Political corruption"},{"ns":0,"exists":"","*":"Pregabalin"},{"ns":0,"exists":"","*":"Prescription Drug Marketing Act"},{"ns":0,"exists":"","*":"Prescription Drug Marketing Act (PDMA)"},{"ns":0,"exists":"","*":"Prescription drug prices in the United States"},{"ns":0,"exists":"","*":"Product sample"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Rosiglitazone"},{"ns":0,"exists":"","*":"Search engine marketing"},{"ns":0,"exists":"","*":"Side Effects (Bass book)"},{"ns":0,"exists":"","*":"Skeptical Inquirer"},{"ns":0,"exists":"","*":"Social media"},{"ns":0,"exists":"","*":"Social network analysis"},{"ns":0,"exists":"","*":"Statin"},{"ns":0,"exists":"","*":"Tablet computer"},{"ns":0,"exists":"","*":"Valdecoxib"},{"ns":0,"exists":"","*":"Valproic acid"},{"ns":0,"exists":"","*":"Ziprasidone"},{"ns":0,"exists":"","*":"Zyprexa"},{"ns":0,"*":"Kiefer Lee"},{"ns":0,"*":"Nicolae Sfetcu"},{"ns":0,"*":"Adoption sequence"},{"ns":0,"*":"Directive 92/28/EEC"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"}],"templates":[{"ns":10,"exists":"","*":"Template:Use dmy dates"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Expand section"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:See also"},{"ns":10,"exists":"","*":"Template:Div col"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Div col end"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Cite"},{"ns":10,"exists":"","*":"Template:Citation"},{"ns":10,"exists":"","*":"Template:Refbegin"},{"ns":10,"exists":"","*":"Template:Refbegin/styles.css"},{"ns":10,"exists":"","*":"Template:ISBN"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Error-small"},{"ns":10,"exists":"","*":"Template:Tl"},{"ns":10,"exists":"","*":"Template:Refend"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Labelled list hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check isxn"},{"ns":828,"exists":"","*":"Module:Error"}],"images":["Lock-green.svg","Wiki_letter_w_cropped.svg"],"externallinks":["https://www.nytimes.com/2015/11/27/opinion/turn-the-volume-down-on-drug-ads.html","https://www.nytimes.com/2015/12/20/opinion/sunday/no-justification-for-high-drug-prices.html","https://www.academia.edu/278465/Chronology_of_Direct-to-Consumer_Advertising_Regulation_in_the_United_States","//www.ncbi.nlm.nih.gov/pubmed/18982834","//doi.org/10.1097/OGX.0b013e31817f1585","//www.ncbi.nlm.nih.gov/pubmed/18713478","http://www.medicine.mcgill.ca/MJM/issues/v08n01/orig_articles/barfett.pdf","//doi.org/10.1056/NEJMp0808659","//www.ncbi.nlm.nih.gov/pubmed/19129523","http://web.law.columbia.edu/sites/default/files/microsites/attorneys-general/files/Following_the_Script.pdf","//doi.org/10.1371/journal.pmed.0040150","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1876413","//www.ncbi.nlm.nih.gov/pubmed/17455991","http://usatoday30.usatoday.com/money/economy/2008-07-10-3919705145_x.htm","http://www.mmm-online.com/docs-are-visited-by-20-reps-a-week-survey-says/article/180995/","http://www.mmslists.com/news-articles/article.asp?ID=9","http://www.phrma.org/sites/default/files/pdf/phrma_marketing_code_2008.pdf","//doi.org/10.1097/MLR.0b013e3181618ee0","//www.ncbi.nlm.nih.gov/pubmed/18362819","http://www.zsassociates.com/news_events/news_media/the_doctor_wont_see_you_mr_pharma_rep_now/","http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=177968","http://www.pharma-mkting.com/glossary/keyopinionleader.htm","http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=395598","http://www.annals.org/cgi/content/abstract/145/4/284","http://www.annals.org/cgi/content/full/145/4/305?etoc","http://doi.acm.org/10.1145/2826972.2826976","//doi.org/10.1145/2826972.2826976","//www.worldcat.org/issn/2166-1200","http://www.chmeds.ac.nz/report.pdf","http://articles.latimes.com/2007/dec/03/health/he-coupons3","http://worldofdtcmarketing.com/the-ax-comes-out-for-pharma-promotional-spending/business-of-the-drug-industry/","https://www.nytimes.com/2010/10/03/business/03psych.html?_r=3&hp=&pagewanted=all","https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?pagewanted=all","https://www.natlawreview.com/article/unbranded-web-sites-fda-finds-violative-promotional-practices","http://www.lnxpharma.com/images/pages/Lnx_Whitepaper_1.pdf","http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=URISERV:l21143&from=EN","http://www.justice.gov/opa/pr/2012/July/12-civ-842.html","http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20-%20PR%20(Final).pdf","http://www.justice.gov/opa/pr/2012/May/12-civ-585.html","http://www.justice.gov/opa/pr/2009/January/09-civ-038.html","http://www.urchpublishing.com/publications/sales/presentation_plan_00.html","http://www.piribo.com/publications/sales_marketing/little_black_book_of_pharma_marketing.html","http://www.marketingoverdose.org/documents/ci_pharma_2007.pdf"],"sections":[{"toclevel":1,"level":"2","line":"To health care providers<sup>&#91;8&#93;</sup>","number":"1","index":"1","fromtitle":"Pharmaceutical_marketing","byteoffset":2877,"anchor":"To_health_care_providers[8]"},{"toclevel":2,"level":"3","line":"PhRMA Code","number":"1.1","index":"2","fromtitle":"Pharmaceutical_marketing","byteoffset":5493,"anchor":"PhRMA_Code"},{"toclevel":2,"level":"3","line":"Free samples","number":"1.2","index":"3","fromtitle":"Pharmaceutical_marketing","byteoffset":7030,"anchor":"Free_samples"},{"toclevel":2,"level":"3","line":"Continuing medical education","number":"1.3","index":"4","fromtitle":"Pharmaceutical_marketing","byteoffset":8525,"anchor":"Continuing_medical_education"},{"toclevel":2,"level":"3","line":"Pharmaceutical representatives","number":"1.4","index":"5","fromtitle":"Pharmaceutical_marketing","byteoffset":8747,"anchor":"Pharmaceutical_representatives"},{"toclevel":2,"level":"3","line":"Peer influence","number":"1.5","index":"6","fromtitle":"Pharmaceutical_marketing","byteoffset":14100,"anchor":"Peer_influence"},{"toclevel":2,"level":"3","line":"Journal articles and technical documentation","number":"1.6","index":"7","fromtitle":"Pharmaceutical_marketing","byteoffset":16432,"anchor":"Journal_articles_and_technical_documentation"},{"toclevel":2,"level":"3","line":"Private and public insurers","number":"1.7","index":"8","fromtitle":"Pharmaceutical_marketing","byteoffset":17456,"anchor":"Private_and_public_insurers"},{"toclevel":1,"level":"2","line":"To consumers","number":"2","index":"9","fromtitle":"Pharmaceutical_marketing","byteoffset":18222,"anchor":"To_consumers"},{"toclevel":2,"level":"3","line":"Drug coupons","number":"2.1","index":"10","fromtitle":"Pharmaceutical_marketing","byteoffset":21400,"anchor":"Drug_coupons"},{"toclevel":1,"level":"2","line":"Economics","number":"3","index":"11","fromtitle":"Pharmaceutical_marketing","byteoffset":22118,"anchor":"Economics"},{"toclevel":1,"level":"2","line":"Regulation and fraud","number":"4","index":"12","fromtitle":"Pharmaceutical_marketing","byteoffset":23903,"anchor":"Regulation_and_fraud"},{"toclevel":2,"level":"3","line":"European Union","number":"4.1","index":"13","fromtitle":"Pharmaceutical_marketing","byteoffset":23929,"anchor":"European_Union"},{"toclevel":2,"level":"3","line":"United States","number":"4.2","index":"14","fromtitle":"Pharmaceutical_marketing","byteoffset":24337,"anchor":"United_States"},{"toclevel":1,"level":"2","line":"Evolution of marketing","number":"5","index":"15","fromtitle":"Pharmaceutical_marketing","byteoffset":28799,"anchor":"Evolution_of_marketing"},{"toclevel":1,"level":"2","line":"See also","number":"6","index":"16","fromtitle":"Pharmaceutical_marketing","byteoffset":31157,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"17","fromtitle":"Pharmaceutical_marketing","byteoffset":31672,"anchor":"References"},{"toclevel":1,"level":"2","line":"Further reading","number":"8","index":"18","fromtitle":"Pharmaceutical_marketing","byteoffset":31717,"anchor":"Further_reading"}],"parsewarnings":[],"displaytitle":"Pharmaceutical marketing","iwlinks":[],"properties":[{"name":"defaultsort","*":"Pharmaceutical Marketing"},{"name":"wikibase_item","*":"Q5254772"}]}}